RxDoctor Payments Data

Margarita Mikhaylova, DO

Neurology · New York, NYNPI 1467892539

Payments from drug & device makers

$30,775in general payments, 2019–2025

Across 1,097 payments — averaging $28.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$16K
  • Pfizer$2K
  • Axsome Therapeutics, Inc.$1K
  • Lilly USA, LLC$1K
  • SK Life Science, Inc.$1K
  • Biogen$919
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$10,70035%
  • Food & beverage$20,05865%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)361$16,069
Pfizer114$1,559
Axsome Therapeutics, Inc.11$1,296
Lilly USA, LLC52$1,102
SK Life Science, Inc.64$1,071
Biogen46$919
Eisai Inc.46$786
Biohaven Pharmaceutical Holding Company Ltd.54$722
Biohaven Pharmaceuticals, Inc.33$712
Teva Pharmaceuticals USA, Inc.34$679
Lundbeck LLC43$647
Amgen24$634
Neurelis, Inc.19$431
UCB, Inc.16$331
Sanofi13$244
Currax Pharmaceuticals LLC14$231
Johnson & Johnson(2 entities)12$229
Novartis12$220
TG Therapeutics, Inc.8$192
Harmony Biosciences LLC6$171
Boston Scientific4$136
Almatica Pharma LLC6$135
Merz Pharmaceuticals, LLC5$133
Scilex Pharmaceuticals Inc.5$117
Amneal Pharmaceuticals LLC5$115
Bristol Myers Squibb5$101
Avanir Pharmaceuticals, Inc.5$94
Kyowa Kirin, Inc.5$89
Catalyst Pharmaceuticals, Inc.4$89
Abbott4$88
Grifols USA, LLC3$88
Tanabe Pharma America, Inc.4$81
Genentech USA, Inc.3$80
Upsher-smith Laboratories LLC4$72
Ipsen Biopharmaceuticals, Inc3$72
Bausch Health US, LLC4$69
Akcea Therapeutics, Inc.3$66
Octapharma USA, Inc.3$65
Otsuka America Pharmaceutical, Inc.3$65
Neurocrine Biosciences, Inc.3$63
Averitas Pharma Inc.2$45
Arbor Pharmaceuticals, Inc.3$44
Takeda Pharmaceuticals U.S.A., Inc.2$44
Banner Life Sciences, LLC2$44
Vertical Pharmaceuticals, LLC2$41
Tonix Medicines, Inc.2$40
Idorsia Pharmaceuticals US Inc2$39
CSL Behring2$37
Inspire Medical Systems, Inc.1$37
Corium, LLC2$35
Argenx US, Inc.1$34
Medtronic1$31
Vanda Pharmaceuticals Inc.1$28
Revance Therapeutics, Inc.1$28
Zyla Life Sciences, Inc.2$25
Life Molecular Imaging Ltd1$24
EMD Serono, Inc.1$21
AstraZeneca1$20
Acadia Pharmaceuticals Inc1$20
Impel Pharmaceuticals LLC1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,775 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$339,710
Medicare patients
242
Services billed
22,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AmpyraDalfampridine14$166,731
Nurtec OdtRimegepant Sulfate18$30,564
QuliptaAtogepant17$20,034
NuedextaDextromethorphan Hbr/Quinidine13$19,459
Zolmitriptan24$11,138
NamzaricMemantine Hcl/Donepezil Hcl12$9,233
Gabapentin182$1,769
Oxcarbazepine24$1,766
Memantine Hcl117$1,762
Donepezil Hcl136$1,244
Eletriptan HbrEletriptan Hydrobromide14$1,055
Tizanidine Hcl78$913
Pregabalin56$582
Quetiapine Fumarate44$503
Carbidopa-LevodopaCarbidopa/Levodopa34$465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$1,559$30,56418 claims
AbbVieQulipta, Namzaric$16,069$29,26729 claims
Avanir Pharmaceuticals, Inc.Nuedexta$94$19,45913 claims
Upsher-smith Laboratories LLCTopiramate$72$26745 claims
Almatica Pharma LLCSertraline Hcl$135$1112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →